Galanin-like Peptide (GALP)

Galanin-like peptide was discovered in 1999 when Takeda researchers purified from porcine hypothalamus a 60-residue peptide detected by its ability to increase guanine-nucleotide binding in GALR2-expressing cells. Sequencing revealed that GALP residues 9 to 21 are completely identical to galanin residues 1 to 13, marking it as a close relative within the galanin family, and receptor-binding studies showed it binds GALR2 with high affinity (roughly 0.24 nanomolar) and GALR1 with lower affinity (around 4.3 nanomolar), giving it a GALR2-preferring profile that contrasts with galanin's relative non-selectivity ^[1].

Anatomically, GALP expression is strikingly restricted. In situ hybridization of adult male rat brain detected GALP messenger RNA essentially only within the arcuate nucleus of the hypothalamus, concentrated in periventricular zones, a localization unlike the broad distribution of galanin and one that overlaps partly with somatostatin neurons ^[2]. This positioning places GALP at a hub for metabolic and neuroendocrine control. Functionally, central GALP influences feeding and body weight and stimulates reproductive axis activity, and it produces a pattern of Fos activation across hypothalamic nuclei, including the diagonal band, caudal preoptic area, arcuate nucleus, and median eminence, that differs from the pattern evoked by galanin, implying GALP engages distinct receptor-mediated pathways ^[3].

GALP arcuate neurons express leptin receptors and respond to changes in energy status, positioning GALP as a downstream mediator of leptin's effects on appetite and reproduction. The peptide has attracted interest as a potential modulator of obesity and reproductive dysfunction, and intranasal GALP has been examined for effects on body weight in preclinical work. GALP remains an endogenous neuropeptide studied for its integrative neuroendocrine role rather than an approved intervention.

As an endogenous peptide studied mainly in animals, GALP has no established human safety profile. Its central roles in appetite, body weight, and reproductive-axis regulation imply that exogenous administration could perturb metabolic and hormonal balance, and effects on body temperature and sexual behavior have been noted in animal work. There is no consumer formulation, no human dosing, and no toxicology suitable for guiding use; it should be regarded as a research peptide.

GALP was identified in 1999 by Ohtaki and colleagues at Takeda Chemical Industries using a functional GALR2 binding assay, and its restricted arcuate expression was mapped shortly afterward by Larm and Gundlach. Through the early 2000s, groups including Steiner and colleagues at the University of Washington elaborated its roles in feeding, body weight, and reproduction, establishing GALP as a leptin-responsive integrator of energy status and fertility within the hypothalamus.

GALP is well established in neuroendocrinology as a genuine galanin-family peptide with a distinctive arcuate localization and a role linking metabolism to reproduction. It is valued as an endogenous signaling molecule and research target, particularly in obesity and fertility biology, but it has not been developed into a therapeutic. It is largely unknown in consumer or nootropic circles despite occasional interest in its intranasal metabolic effects.